Open Access Research article

Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial

Brinda Emu1, Diana Luca1, Carolyn Offutt1, Jane L Grogan1, Bernadette Rojkovich2, Marna B Williams1, Meina T Tang1, Jim Xiao1, June H Lee3 and John C Davis1*

Author Affiliations

1 Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA

2 Polyclinic of the Hospital Brothers of St John of God in Budapest, 114 PO Box 54, Budapest H-1525, Hungary

3 University of California at San Francisco, Box 0558, 185 Berry Street 5300, San Francisco, CA 94107, USA

For all author emails, please log on.

Arthritis Research & Therapy 2012, 14:R6  doi:10.1186/ar3554

Published: 8 January 2012

Additional files

Additional file 1:

Maximum decreases in CXCL13 (pharmacodynamic effects) were consistently observed at serum pateclizumabconcentrations > 1 to 10 μg/ml across all cohorts. The pateclizumab (circles) and CXCL13 (triangles) concentrations are presented as means ± SD.

Format: DOC Size: 66KB Download file

This file can be viewed with: Microsoft Word Viewer

Open Data